Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -11% Improvement Relative Risk c19early.org/u Yang et al. Budesonide for COVID-19 LATE TREATMENT Favors budesonide Favors control
The relationship between oxygen therapy, drug therapy, and COVID-19 mortality
Yang et al., Open Medicine, doi:10.1515/med-2022-0569
Yang et al., The relationship between oxygen therapy, drug therapy, and COVID-19 mortality, Open Medicine, doi:10.1515/med-2022-0569
Aug 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 185 hospitalized COVID-19 patients in China, showing no significant difference in mortality with budesonide use in unadjusted results. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 10.8% higher, RR 1.11, p = 0.85, treatment 30 of 125 (24.0%), control 13 of 60 (21.7%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yang et al., 31 Aug 2022, retrospective, China, peer-reviewed, median age 62.0, 12 authors, study period 1 January, 2020 - 29 February, 2020.
Contact: 2205603@tongji.edu.cn, 1220775601@qq.com, 29553185@qq.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBudesonideAll
Abstract: Open Medicine 2022; 17: 1833–1839 Research Article Ling Yang*#, Guoxi Chen#, Yuyang Cai#, Ye An#, Xiaopan Li#, Ying Chen, Cheng Xu, Chen Ji, Xing Lan, Yaling Wang, Hai Huang*, Li Han* The relationship between oxygen therapy, drug therapy, and COVID-19 mortality https://doi.org/10.1515/med-2022-0569 received March 17, 2022; accepted August 24, 2022 Abstract: Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19). We conducted a retrospective study of COVID-19 inpatients in Wuhan Pulmonary Hospital (Wuhan, China) from January 1 to February 29, 2020. The subjects were divided into four groups due to different treatment regimes. We used the Kaplan–Meier method to determine the cumulative rates of in-hospital death and the Cox proportional hazard model to calculate the risk factors and corresponding hazard ratios. A total of 185 patients were included in this study. The median age of the patients was 62 years, including 94 men and 91 women. Kaplan–Meier analysis demonstrated that mortality was higher in older patients, higher in men, and lower in the low-flow oxygen therapy group. Body mass  # Ling Yang, Guoxi Chen, Yuyang Cai, Ye An, Xiaopan Li contributed equally to this work.  * Corresponding author: Ling Yang, Department of Geriatrics, Shanghai Fourth People’s Hospital Affiliated to Tongji University, Shanghai, China, e-mail: 2205603@tongji.edu.cn * Corresponding author: Hai Huang, Tuberculosis department, Wuhan Pulmonary Hospital, Wuhan, China, e-mail: 1220775601@qq.com * Corresponding author: Li Han, Department of Geriatrics, Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai, China, e-mail: 29553185@qq.com Guoxi Chen, Xing Lan, Yaling Wang: Tuberculosis department, Wuhan Pulmonary Hospital, Wuhan, China Yuyang Cai: School of Public Health, Shanghai Jiaotong University School of Medicine, Shanghai, China Ye An, Ying Chen, Cheng Xu: Department of Geriatrics, Shanghai Jiaotong University School of Medicine, Xinhua Hospital, Shanghai, China Xiaopan Li: Pudong Institute of Preventive Medicine, Fudan University, Shanghai, China Chen Ji: Warwick Clinical Trials Unit, Warwick Medical School, Warwick, Great Britain Open Access. © 2022 the author(s), published by De Gruyter. License. index (BMI) had no influence on mortality, as well as high flow oxygen therapy, Lopinavir–ritonavir (LPV/r) therapy, and the interferon-alpha add LPV/r therapy. Cox proportional hazard regression confirmed that the low flow oxygen therapy was independent protective factor for in-hospital death after adjusting for age, gender, and BMI. In conclusion, the mortality was higher in older patients, higher in men, and lower in the low-flow oxygen therapy group. BMI had no influence on mortality, as well as high flow oxygen therapy, LPV/r therapy, and interferon-alpha add LPV/r therapy. Keywords: drugs treatment, COVID-19, pneumonia, mortality
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit